Published Date: 06 Mar 2023
Diabetic retinopathy is a leading cause of vision loss, with diabetic retinopathy (DDR) representing the most severe form of...
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
2.
Discovery of breast cancer treatment resistance mechanism could lead to new hope for some
3.
O. A. J. Simpson passes away from cancer.
4.
Data indicate 1 in 3 US adults unaware of connection between HPV and cancers
5.
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
1.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
Precision Oncology: Tailoring Cancer Treatment for the Individual
4.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
5.
Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation